"Over the past few months we have been recasting deCODE's business around what we do best: discover genetic risk factors for common diseases and apply those findings in tests and services that can improve the prevention and treatment of disease. Our partnership with Celera is one facet of this strategy. Preliminary acceptance of our US patent application for one of our major genetic risk markers also underscores the wisdom of our approach to intellectual property, both for differentiating our products from the rest of the field and for pursuing additional licensing partnerships. At the same time, we are engaged in negotiations on large-scale sequencing collaborations, debt restructuring and equity financing, and on the sale of certain business units and therapeutics programs. Our aim in pursuing all of these opportunities is to position deCODE to capture the commercial potential of our leadership in human genetics," said Kari Stefansson, CEO of deCODE.
Recent operating highlights include: Product Development and Partnerships - Celera. Last month, deCODE entered into agreements with Celera Corporation under which it has granted Celera non-exclusive worldwide licenses to deCODE's genetic markers for increased risk of major cardiovascular and metabolic diseases, including heart attack, stroke, atrial fibrillation (AF) and type 2 diabetes (T2D). The markers include SNPs discovered by deCODE on chromosome 9p21 linked to increased risk of heart attack and types of aneurysm, on chromosome 4q25 conferring
|SOURCE deCODE genetics Inc|
Copyright©2009 PR Newswire.
All rights reserved